

$R_6$ is selected from H, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, -C(O)$CH_3$, phenyl, -O-phenyl, benzyl, -O-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, -$NO_2$, -$NH_2$, -CN, -$CF_3$, or -OH;

$R_7$ is selected from -$(CH_2)_n$-COOH, -$(CH_2)_n$-N-($C_1$-$C_6$ alkyl)$_2$, -$(CH_2)_n$-NH-($C_1$-$C_6$ alkyl), -$CF_3$, $C_1$-$C_6$ alkyl, $C_3$-$C_5$ cycloalkyl, $C_1$-$C_6$ alkoxy, -NH-($C_1$-$C_6$ alkyl), -N-($C_1$-$C_6$ alkyl)$_2$, pyridinyl, thienyl, furyl, pyrrolyl, quinolyl, $(CH_2)_n$phenyl, phenyl,-O-phenyl, benzyl, -O-benzyl, adamantyl, or morpholinyl, -$(CH_2)_n$-phenyl-O-phenyl, -$(CH_2)_n$-phenyl-$CH_2$-phenyl, -$(CH_2)_n$-O-phenyl-$CH_2$-phenyl, -$(CH_2)_n$-phenyl-(O-$CH_2$-phenyl)$_2$,the rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, -$NH_2$, -$NO_2$, -$CF_3$,$CO_2H$, or -OH;

$R_2$ is selected from H, halogen, -$CF_3$, -OH, -$C_1$-$C_{10}$ alkyl, $C_1$-$C_{10}$ alkoxy, -CHO, -CN, -$NO_2$, -$NH_2$, -NH-$C_1$-$C_6$ alkyl, -N($C_1$-$C_6$ alkyl)$_2$, -N-$SO_2$-$C_1$-$C_6$ alkyl, or -$SO_2$-$C_1$-$C_6$ alkyl;

$R_3$ is selected from H, -$CF_3$, $C_1$-$C_6$ lower alkyl, $C_1$-$C_6$ lower alkoxy, $C_3$-$C_{10}$ cycloalkyl, -$C_1$-$C_6$ alkyl, -$C_3$-$C_{10}$ cycloalkyl, -CHO, halogen, $(CH_2)_n$C(O)$NH_2$ or a moiety of the formula –$L^1$-$M^1$:

$L^1$ indicates a linking or bridging group of the formulae -$(CH_2)_n$-, -S-, -O-, -C(O)-, -$(CH_2)_n$-C(O)-, -$(CH_2)_n$-C(O)-$(CH_2)_n$-, -$(CH_2)_n$-O-$(CH_2)_n$-, or -$(CH_2)_n$-S-$(CH_2)_n$-, C(O)C(O)X, -$(CH_2)_n$-N-$(CH_2)_n$-;

$M^1$ is selected from:

a) H, the group of $C_1$-$C_6$ lower alkyl, $C_1$-$C_6$ lower alkoxy, $C_3$-$C_{10}$ cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, $C_1$-$C_{10}$ alkyl, $C_1$-$C_{10}$ alkoxy, $-NO_2$, $-NH_2$, -CN, or $-CF_3$; or

b) a five-membered heterocyclic ring containing one or two ring heteroatoms selected from N, S or O, the five-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, $C_1$-$C_{10}$ alkyl, $C_1$-$C_{10}$ alkoxy, $-NO_2$, $-NH_2$, -CN, or $-CF_3$; or

c) a six-membered heterocyclic ring containing one, two or three ring heteroatoms selected from N, S or O, the six-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, $C_1$-$C_{10}$ alkyl, $C_1$-$C_{10}$ alkoxy, -CHO, $-NO_2$, $-NH_2$, -CN, $-CF_3$ or -OH; or

d) a bicyclic ring moiety containing from 8 to 10 ring atoms and optionally containing from 1 to 3 ring heteroatoms selected from N, S or O, the bicyclic ring moiety being optionally substituted by from 1 to 3 substituents selected from halogen, $C_1$-$C_{10}$ alkyl, $C_1$-$C_{10}$ alkoxy, -CHO, $-NO_2$, $-NH_2$, -CN, $-CF_3$ or -OH;

$R_4$ is selected from the group of $C_1$-$C_6$ lower alkyl, $C_1$-$C_6$ lower alkoxy, $-(CH_2)_n$-$C_3$-$C_6$ cycloalkyl, $-(CH_2)_n$-S-$(CH_2)_n$-$C_3$-$C_5$ cycloalkyl, $-(CH_2)_n$-O-$(CH_2)_n$-$C_3$-$C_5$ cycloalkyl, or the groups of:

a) $-(CH_2)_n$-phenyl-O-phenyl, $-(CH_2)_n$-phenyl-$CH_2$-phenyl, $-(CH_2)_n$-O-phenyl-$CH_2$-phenyl, $-(CH_2)_n$-phenyl-(O-$CH_2$-phenyl)$_2$, or a moiety of the formulae:



Page 3 of 53

wherein n is independently selected in each appearance as an integer from 0 to 3, Y is $C_3$-$C_5$ cycloalkyl, phenyl, benzyl, napthyl, pyridinyl, quinolyl, furyl, thienyl or pyrrolyl; rings of these groups being optionally substituted by from 1 to 3 substituents selected from H, halogen, -$CF_3$, -OH, -$C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, -$NH_2$, -$NO_2$ or a five membered heterocyclic ring containing one heteroatom selected from N, S, or O; or

b) a moiety of the formulae -$(CH_2)_n$-A, -$(CH_2)_n$-S-A, or -$(CH_2)_n$-O-A, wherein A is the moiety:




wherein

D is H, $C_1$-$C_6$ lower alkyl, $C_1$-$C_6$ lower alkoxy, or -$CF_3$;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, substituents selected from H, halogen, -$CF_3$, -OH, -$C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, or -$NO_2$; or

c) *a moiety of the formulae:*




,




,



,


,


, or


;

wherein Z is O or S and the phenyl and pyrimidinyl rings of each moiety are optionally and independently substituted by from 1 to 3 substituents selected from halogen, $-CF_3$, -OH, $-C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, $-NH_2$, or $-NO_2$; or

d) a moiety of the formula $-L^2-M^2$, wherein:

$L^2$ indicates a linking or bridging group of the formulae $-(CH_2)_n-$, -S-, -O-, $-SO_2-$, -C(O)-, $-(CH_2)_n-C(O)-$, $-(CH_2)_n-C(O)-(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_n-$, or $-(CH_2)_n-S-(CH_2)_n-$, -C(O)C(O)X;
where X = O, N

$M^2$ is selected from the group of $C_1$-$C_6$ lower alkyl, $C_1$-$C_6$ lower alkoxy, $C_3$-$C_{10}$ cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, $C_1$-$C_{10}$ alkyl, $C_1$-$C_{10}$ alkoxy, $-NO_2$, $-NH_2$, -CN, or $-CF_3$; or

i) a five-membered heterocyclic ring containing one or two ring heteroatoms selected from N, S or O, the five-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, $C_1$-$C_{10}$ alkyl, $C_1$-$C_{10}$ alkoxy, $-NO_2$, $-NH_2$, -CN, or $-CF_3$; or

ii) a six-membered heterocyclic ring containing one, two or three ring heteroatoms selected from N, S or O, the six-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, $C_1$-$C_{10}$ alkyl, $C_1$-$C_{10}$ alkoxy, -CHO, -$NO_2$, -$NH_2$, -CN, -$CF_3$ or -OH; or

*iii) a bicyclic ring moiety containing from 8 to 10 ring atoms and optionally* containing from 1 to 3 ring heteroatoms selected from N, S or O, the bicyclic ring moiety being optionally substituted by from 1 to 3 substituents selected from halogen, $C_1$-$C_{10}$ alkyl, $C_1$-$C_{10}$ alkoxy, -CHO, -$NO_2$, -$NH_2$, -CN, -$CF_3$ or -OH;

n is an integer from 0 to 3;

$R_5$ is selected from -COOH, -C(O)-COOH, -$(CH_2)_n$-C(O)-COOH, -$(CH_2)_n$-COOH, $(CH_2)_n$-CH=CH-COOH, -$(CH_2)_n$-tetrazole, -$CH_2$-phenyl-C(O)-benzothiazole, or


($C_1$-$C_6$ lower alkyl) ,


($C_1$-$C_6$ lower haloalkyl) ,



,



;

or a moiety selected from the formulae $-L^3-M^3$;

wherein $L^3$ is a bridging or linking moiety selected from a chemical bond, -$(CH_2)_n$-, -S-, -O-, -$SO_2$-, -C(O)-, -$(CH_2)_n$-C(O)-, -$(CH_2)_n$-C(O)-$(CH_2)_n$-, -$(CH_2)_n$-O-$(CH_2)_n$-,-$(CH_2)_n$-S-$(CH_2)_n$-, -C(Z)-N($R_6$)-, -C(Z)-N($R_6$)-$(CH_2)_n$-, -C(O)-C(Z)-N($R_6$)-, -C(O)-C(Z)-N($R_6$)-$(CH_2)_n$-, -C(Z)-NH-

$SO_2$-, -C(Z)-NH-$SO_2$-$(CH_2)_n$-, -$(CH_2)_n$-S-$(CH_2)_n$-, -$(CH_2)_n$-SO-$(CH_2)_n$-, -$(CH_2)_n$-$SO_2$-$(CH_2)_n$-, or –$(CH_2)_n$-CH=CH-$(CH_2)_n$-O-;

$M^3$ is selected from the group of -COOH, -$(CH_2)_n$-COOH, -$(CH_2)_n$-C(O)-COOH, tetrazole,










or

, or


where $R_8$, $R_9$ or $R_{10}$ can be attached anywhere in the cyclic or bicyclic system,
n is an integer from 0 to 3;

$R_8$, in each appearance, is independently selected from H, -COOH, -$(CH_2)_n$-COOH, -$(CH_2)_n$-C(O)-COOH, tetrazole, -C(O)-$NH_2$, -$(CH_2)_n$-C(O)-$NH_2$,


, or

;

n is an integer from 0 to 3;

$R_9$ is selected from H, halogen, $-CF_3$, -OH, -COOH, $-(CH_2)_n$-COOH, $-(CH_2)_n$-C(O)-COOH, $-C_1$-$C_6$ alkyl, $-O-C_1$-$C_6$ alkyl, $-NH(C_1$-$C_6$ alkyl), or $-N(C_1$-$C_6$ alkyl$)_2$;

n is an integer from 0 to 3;

$R_{10}$ is selected from the group of H, halogen, $-CF_3$, -OH, $-(CH_2)_n$-COOH, $-(CH_2)_n$-C(O)-COOH, $-C_1$-$C_6$ alkyl, $-O-C_1$-$C_6$ alkyl, $-NH(C_1$-$C_6$ alkyl), $-N(C_1$-$C_6$ alkyl$)_2$,


,

,

,


,

,

or

or

,


,

,


,


, or

;

$R_{11}$ is selected from H, $C_1$-$C_6$ lower alkyl, $C_1$-$C_6$ cycloalkyl, $-CF_3$, -COOH, $-(CH_2)_n$-COOH, $-(CH_2)_n$-C(O)-COOH,



with a proviso that the complete moiety at the indole or indoline 1-position created by any combination of $R_5$, $R_8$, $R_9$, $R_{10}$, and/or $R_{11}$ shall contain at least one acidic moiety selected from or containing a carboxylic acid, a tetrazole, or a moiety of the formulae: -C(O)-$NH_2$, -$(CH_2)_n$-C(O)-$NH_2$,



n is an integer from 0 to 3;
or a pharmaceutically acceptable salt thereof.

2 (Amended). A compound of Claim 1 wherein:

$R_1$ and $R_{1'}$ are independently selected from H, halogen, -$CF_3$, -OH, -$C_1$-$C_{10}$ alkyl, -S-$C_1$-$C_{10}$ alkyl, $C_1$-$C_{10}$ alkoxy, -CN, -$NO_2$, -$NH_2$, -HN($C_1$-$C_6$), -N($C_1$-$C_6$)$_2$, phenyl, -O-phenyl, -S-phenyl, benzyl, -O-benzyl, or -S-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, -$NO_2$, -$NH_2$, -CN, -$CF_3$, or -OH;

$M^1$ is selected from: H, $C_1$-$C_6$ lower alkyl, $C_1$-$C_6$ lower alkoxy, $C_3$-$C_{10}$ cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, $C_1$-$C_{10}$ alkyl, $C_1$-$C_{10}$ alkoxy, -$NO_2$, -$NH_2$, -CN, or -$CF_3$;

$R_4$ is a moiety of the formulae -$(CH_2)_n$-A, -$(CH_2)_n$-S-A, or -$(CH_2)_n$-O-A, wherein A is the moiety:



wherein

D is H, $C_1$-$C_6$ lower alkyl, $C_1$-$C_6$ lower alkoxy, or -$CF_3$;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3 substituents selected from H, halogen, -$CF_3$, -OH, -$C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, or -$NO_2$;
*or a pharmaceutically acceptable salt thereof.*

3 (Amended). A compound of Claim 2 wherein $R_4$ is the moiety:




B and C are phenyl optionally substituted by from 1 to 3 substituents selected from H, halogen, -$CF_3$, -OH, -$C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, or -$NO_2$; and $R_1$, $R_{1'}$, $R_2$, $R_3$, $R_5$, $L^1$, $M^1$ and D are as defined in Claim 2; or a pharmaceutically acceptable salt thereof.

4 (Amended). A compound of Claim 1 wherein:

$R_4$ is selected from the group of $C_1$-$C_6$ lower alkyl, $C_1$-$C_6$ lower alkoxy, -$(CH_2)_n$-$C_3$-$C_6$ cycloalkyl, -$(CH_2)_n$-S-$(CH_2)_n$-$C_3$-$C_5$ cycloalkyl, -$(CH_2)_n$-O-$(CH_2)_n$-$C_3$-$C_5$ cycloalkyl, or the groups of:

a) a moiety of the formulae -$(CH_2)_n$-A, -$(CH_2)_n$-S-A, or -$(CH_2)_n$-O-A, wherein A is *the moiety*:




wherein

D is H, $C_1$-$C_6$ lower alkyl, $C_1$-$C_6$ lower alkoxy, or -$CF_3$;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, substituents selected from H, halogen, -$CF_3$, -OH, -$C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, or -$NO_2$; or

b) a moiety of the formula -$L^2$-$M^2$, wherein $L^2$ and $M^2$ are as defined in claim 1;

$R_5$ is selected from -COOH, -C(O)-COOH, -$(CH_2)_n$-C(O)-COOH, -$(CH_2)_n$-COOH, $(CH_2)_n$-CH=CH-COOH, -$(CH_2)_n$-tetrazole, -$CH_2$-phenyl-C(O)-benzothiazole, or



or a moiety selected from the formulae $-L^3-M^3$ wherein $L^3$ and $M^3$ are as defined in claim 1; or a pharmaceutically acceptable salt thereof.

5 (Amended). A compound of Claim 1 wherein:

$R_1$ is H;

$R_4$ is selected from the group of $C_1$-$C_6$ lower alkyl, $C_1$-$C_6$ lower alkoxy, -$(CH_2)_n$-$C_3$-$C_6$ cycloalkyl, -$(CH_2)_n$-S-$(CH_2)_n$-$C_3$-$C_5$ cycloalkyl, -$(CH_2)_n$-O-$(CH_2)_n$-$C_3$-$C_5$ cycloalkyl, or a moiety of the formulae -$(CH_2)_n$-A, -$(CH_2)_n$-S-A, or -$(CH_2)_n$-O-A, wherein A is the moiety:



wherein

D is H, $C_1$-$C_6$ lower alkyl, $C_1$-$C_6$ lower alkoxy, or -$CF_3$;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, substituents selected from H, halogen, -$CF_3$, -OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, or -$NO_2$;

$R_5$ is selected from -COOH, -C(O)-COOH, -$(CH_2)_n$-C(O)-COOH, -$(CH_2)_n$-COOH, $(CH_2)_n$-CH=CH-COOH, -$(CH_2)_n$-tetrazole, or



or a moiety selected from the formulae $-L^3-M^3$;

wherein $L^3$ is a bridging or linking moiety selected from a chemical bond, $-(CH_2)_n-$, $-SO_2-$, $-C(O)-$, $-(CH_2)_n-C(O)-$, $-(CH_2)_n-C(O)-(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_n-$,$-(CH_2)_n-S-(CH_2)_n-$, $-(CH_2)_n-SO-(CH_2)_n-$, $-(CH_2)_n-SO_2-(CH_2)_n-$, or $-(CH_2)_n-CH=CH-(CH_2)_n-O-$;

$M^3$ is selected from the group of -COOH, $-(CH_2)_n-COOH$, $-(CH_2)_n-C(O)-COOH$, tetrazole,



where $R_8$, $R_9$ can be attached anywhere in the cyclic or bicyclic system,
n is an integer from 0 to 3;

$R_8$, in each appearance, is independently selected from H, -COOH, $-(CH_2)_n-COOH$, $-(CH_2)_n-C(O)-COOH$, tetrazole, $-C(O)-NH_2$, $-(CH_2)_n-C(O)-NH_2$,



n is an integer from 0 to 3;

$R_9$ is selected from H, halogen, $-CF_3$, -OH, -COOH, $-(CH_2)_n$-COOH, $-(CH_2)_n$-C(O)-COOH, $-C_1$-$C_6$ alkyl, $-O-C_1$-$C_6$ alkyl, $-NH(C_1$-$C_6$ alkyl), or $-N(C_1$-$C_6$ alkyl$)_2$;

n is an integer from 0 to 3;

with a proviso that the complete moiety at the indole or indoline 1-position created by any combination of $R_5$, $R_8$, $R_9$, shall contain at least one acidic moiety selected from or containing a carboxylic acid, a tetrazole, or a moiety of the formulae: $-C(O)-NH_2$, $-(CH_2)_n-C(O)-NH_2$,




or

;

n is an integer from 0 to 3;

or a pharmaceutically acceptable salt thereof.

6 (Amended). A compound of Claim 1 wherein:

$R_1$ is selected from H, halogen, $-CF_3$, -OH, $-C_1$-$C_{10}$ alkyl, $-S-C_1$-$C_{10}$ alkyl, $C_1$-$C_{10}$ alkoxy, -CN, $-NO_2$, $-NH_2$, $-HN(C_1$-$C_6)$, $-N(C_1$-$C_6)_2$, phenyl, -O-phenyl, -S-phenyl, benzyl, -O-benzyl, -S-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, $C_1$-$C_6$ alkyl, $C_1$-$C_8$ alkoxy, $-NO_2$, $-NH_2$, -CN, $-CF_3$, or -OH;

or $R_1$ and $R_{1'}$ are independently a moiety of the formulae:

or a moiety of the formulae:


,

,

,

,

,

,
or

;

$R_6$ and $R_7$ are as defined in claim 1;

$R_3$ is selected from H, $-CF_3$, $C_1$-$C_6$ lower alkyl, $C_1$-$C_6$ lower alkoxy, $C_3$-$C_{10}$ cycloalkyl, -$C_1$-$C_6$ alkyl, -$C_3$-$C_{10}$ cycloalkyl, -CHO, halogen, $(CH_2)_nC(O)NH_2$ or a moiety of the formula $-L^1$-$M^1$:

$L^1$ indicates a linking or bridging group of the formulae $-(CH_2)_n-$, $-C(O)-$, $-(CH_2)_n-C(O)-$, $-(CH_2)_n-C(O)-(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_n-$, or $-(CH_2)_n-S-(CH_2)_n-$, C(O)C(O)X, $-(CH_2)_n-N-(CH_2)_n$;

$M^1$ is selected from H, the group of $C_1$-$C_6$ lower alkyl, $C_1$-$C_6$ lower alkoxy, $C_3$-$C_{10}$ cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, $C_1$-$C_{10}$ alkyl, $C_1$-$C_{10}$ alkoxy, -$NO_2$, -$NH_2$, -CN, or -$CF_3$;

$R_4$ is selected from the group of $C_1$-$C_6$ lower alkyl, $C_1$-$C_6$ lower alkoxy, $-(CH_2)_n-C_3-C_6$ cycloalkyl, $-(CH_2)_n-S-(CH_2)_n-C_3-C_5$ cycloalkyl, $-(CH_2)_n-O-(CH_2)_n-C_3-C_5$ cycloalkyl, or a moiety of the formulae $-(CH_2)_n-A$, $-(CH_2)_n-S-A$, or $-(CH_2)_n-O-A$, wherein A is the moiety:




wherein

D is H, $C_1$-$C_6$ lower alkyl, $C_1$-$C_6$ lower alkoxy, or -$CF_3$;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, substituents selected from H, halogen, -$CF_3$, -OH, -$C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, or -$NO_2$;

$R_5$ is selected from -COOH, -C(O)-COOH, $-(CH_2)_n-C(O)-COOH$, $-(CH_2)_n-COOH$, $(CH_2)_n-CH=CH-COOH$, $-(CH_2)_n-$tetrazole, or a moiety selected from the formulae $-L^3-M^3$; wherein $L^3$ is a bridging or linking moiety selected from a chemical bond, $-(CH_2)_n-$, $-(CH_2)_n-C(O)-(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_n-$,$-(CH_2)_n-S-(CH_2)_n-$, $-(CH_2)_n-SO-(CH_2)_n-$, $-(CH_2)_n-SO_2-(CH_2)_n-$, or $-(CH_2)_n-CH=CH-(CH_2)_n-O-$;

$M^3$ is selected from the group of -COOH, $-(CH_2)_n-COOH$, $-(CH_2)_n-C(O)-COOH$, tetrazole,



where $R_8$, $R_9$ can be attached anywhere in the cyclic or bicyclic system,
n is an integer from 0 to 3;

$R_8$, in each appearance, is independently selected from H, -COOH, $-(CH_2)_n$-COOH, $-(CH_2)_n$-C(O)-COOH, tetrazole, -C(O)-$NH_2$, $-(CH_2)_n$-C(O)-$NH_2$,



n is an integer from 0 to 3;

$R_9$ is selected from H, halogen, $-CF_3$, -OH, -COOH, $-(CH_2)_n$-COOH, $-(CH_2)_n$-C(O)-COOH, $-C_1$-$C_6$ alkyl, -O-$C_1$-$C_6$ alkyl, -NH($C_1$-$C_6$ alkyl), or -N($C_1$-$C_6$ alkyl)$_2$;
n an integer from 0 to 3;

with a proviso that the complete moiety at the indole or indoline 1-position created by any combination of $R_5$, $R_8$, $R_9$, shall contain at least one acidic moiety selected from or containing a carboxylic acid, a tetrazole, or a moiety of the formulae: -C(O)-$NH_2$, $-(CH_2)_n$-C(O)-$NH_2$,



n is an integer from 0 to 3;
or a pharmaceutically acceptable salt thereof.

7 (Amended). A compound of Claim 1 wherein:

$R_7$ is selected from -OH, $-CF_3$, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, -NH-($C_1$-$C_6$ alkyl), -N-($C_1$-$C_6$ alkyl)$_2$, pyridinyl, thienyl, furyl, pyrrolyl, phenyl, -O-phenyl, benzyl, -O-benzyl, the rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, -CN, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, $-NO_2$, $-NH_2$, $-CF_3$, or -OH;

$R_3$ is selected from H, $-C_1$-$C_{10}$ alkyl, $-(CH_2)$-OH, $(CH_2)_nC(O)NH_2$, $-CH_2$-O-($C_1$-$C_6$ alkyl, $-CH_2$-O-$CH_2$-phenyl, $-CH_2$-N-($C_1$-$C_6$ alkyl), $-CH_2$-N-$CH_2$-phenyl, the phenyl rings of which are optionally substituted by 1 or 2 groups selected from H, halogen, $-CF_3$ or $-C_1$-$C_6$ alkyl;

X is O or N

n = 0 or 1;

$R_4$ is a moiety of the formulae $-(CH_2)_n$-A, $-(CH_2)_n$-S-A, or $-(CH_2)_n$-O-A, wherein A is the moiety:




wherein

D is H, $C_1$-$C_6$ lower alkyl, $C_1$-$C_6$ lower alkoxy, or $-CF_3$;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl or pyrrolyl groups, each optionally substituted by from 1 to 3, substituents selected from H, halogen, $-CF_3$, -OH, $-C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, or $-NO_2$;

$R_5$ is a moiety selected from the groups of:



wherein $L^1$ is a bridging or linking moiety selected from a chemical bond, -$(CH_2)_{n'}$-, -$(CH_2)_{n'}$-C(O)-$(CH_2)_{n'}$-, -$(CH_2)_{n'}$-O-$(CH_2)_{n'}$-,-$(CH_2)_{n'}$-S-$(CH_2)_{n'}$-, -$(CH_2)_{n'}$-SO-$(CH_2)_{n'}$-, -$(CH_2)_{n'}$-$SO_2$-$(CH_2)_{n'}$-, or –$(CH_2)_{n'}$-CH=CH-$(CH_2)_{n'}$-O-;

*where n' is an integer from 0 to 5;*

$R_9$ is selected from –$CF_3$, -$C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, -NH($C_1$-$C_6$ alkyl), or -N($C_1$-$C_6$ alkyl)$_2$,

n in each instance is independently selected as an integer from 0 to 3;

or a pharmaceutically acceptable salt thereof.

8 (Amended). A compound of Claim 1 having the formulae:



wherein:

$R_1$ is selected from H, halogen, $-CF_3$, -OH, $-C_1$-$C_{10}$ alkyl, $-S-C_1$-$C_{10}$ alkyl, $C_1$-$C_{10}$ alkoxy, -CN, $-NO_2$, $-NH_2$, $-HN(C_1$-$C_6)$, $-N(C_1$-$C_6)_2$, phenyl, -O-phenyl, -S-phenyl, benzyl, -O-benzyl, -S-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, $-NO_2$, $-NH_2$, -CN, $-CF_3$, or -OH;

$R_2$ is selected from H, halogen, $-CF_3$, -OH, $-C_1$-$C_{10}$ alkyl, $C_1$-$C_{10}$ alkoxy, -CHO, -CN, $-NO_2$, $-NH_2$, $-NH-C_1$-$C_6$ alkyl, $-N(C_1$-$C_6$ alkyl$)_2$, $-N-SO_2-C_1$-$C_6$ alkyl, or $-SO_2-C_1$-$C_6$ alkyl;

$R_3$ is selected from H, $-C_1$-$C_{10}$ alkyl, $-(CH_2)$-OH, $(CH_2)_nC(O)NH_2$, $-CH_2-O-(C_1$-$C_6$ alkyl), $-CH_2-O-CH_2$-phenyl, $-CH_2-N-(C_1$-$C_6$ alkyl), $-CH_2-N-CH_2$-phenyl, the phenyl rings of which are optionally substituted by 1 or 2 groups selected from H, halogen, $-CF_3$ or $-C_1$-$C_6$ alkyl;

n = 0 or 1.

$R_4$ is a moiety of the formulae $-(CH_2)_n$-A, $-(CH_2)_n-S$-A, or $-(CH_2)_n-O$-A, wherein A is the moiety:




wherein

D is H, $C_1$-$C_6$ lower alkyl, $C_1$-$C_6$ lower alkoxy, or $-CF_3$;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl or pyrrolyl groups, each optionally substituted by from 1 to 3, substituents selected from H, halogen, $-CF_3$, -OH, $-C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, or $-NO_2$;

$R_5$ is a moiety selected from the groups of:



wherein $L^1$ is a bridging or linking moiety selected from a chemical bond, -$(CH_2)_n$-, -$(CH_2)_n$-C(O)-$(CH_2)_n$-, -$(CH_2)_n$-O-$(CH_2)_n$-,-$(CH_2)_n$-S-$(CH_2)_n$-, -$(CH_2)_n$-SO-$(CH_2)_n$-, -$(CH_2)_n$-$SO_2$-$(CH_2)_n$-, or –$(CH_2)_n$-CH=CH-$(CH_2)_n$-O-;
where n = 0-5

$R_9$ is selected from –$CF_3$, -$C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, -NH($C_1$-$C_6$ alkyl), or -N($C_1$-$C_6$ alkyl)$_2$,

*n in each instance is independently selected as an integer from* 0 to 3,
or a pharmaceutically acceptable salt thereof.

9 (Amended). A compound of Claim 1 having the formulae:



wherein:

$R_1$ is selected from H, halogen, -$CF_3$, -OH, -CN, -$NO_2$, -$NH_2$, -HN($C_1$-$C_6$), -N($C_1$-$C_6$)$_2$, phenyl, -N-$SO_2$-$C_1$-$C_6$ alkyl, or -$SO_2$-$C_1$-$C_6$ alkyl;

$R_2$ is selected from H, halogen, $-CF_3$, -OH, , -CN, $-NO_2$, $-NH_2$, $-NH-C_1-C_6$ alkyl, $-N(C_1-C_6$ alkyl$)_2$, $-N-SO_2-C_1-C_6$ alkyl, or $-SO_2-C_1-C_6$ alkyl;

$R_3$ is selected from H, $-C_1-C_{10}$ alkyl, $-(CH_2)-OH$, $(CH_2)_nC(O)NH_2$, $-CH_2-O-(C_1-C_6$ alkyl), $-CH_2-O-CH_2$-phenyl, $-CH_2-N-(C_1-C_6$ alkyl), $-CH_2-N-CH_2$-phenyl, the phenyl rings of which are optionally substituted by 1 or 2 groups selected from H, halogen, $-CF_3$ or $-C_1-C_6$ alkyl;

n = 0 or 1.

$R_5$ is a moiety selected from the groups of:




wherein $L^1$ is a bridging or linking moiety selected from a chemical bond, $-(CH_2)_{n'}-$, $-(CH_2)_{n'}-C(O)-(CH_2)_{n'}-$, $-(CH_2)_{n'}-O-(CH_2)_{n'}-$,$-(CH_2)_{n'}-S-(CH_2)_{n'}-$, $-(CH_2)_{n'}-SO-(CH_2)_{n'}-$, $-(CH_2)_{n'}-SO_2-(CH_2)_{n'}-$, or $-(CH_2)_{n'}-CH=CH-(CH_2)_{n'}-O-$;

n' in each instance is independently selected as an integer from 0 to 5;

or a pharmaceutically acceptable salt thereof.

---

REMARKS

Claims 1-20 are pending. Although the Office Action Summary states that claims 10-15 have been allowed, claims 1, 5-7 and 20 have been rejected, and claims 1-9 and 16-20 have been objected to, in the office action it appears that all 20 claims have been rejected and claims 1-9 and 16-20 have been objected to. Reconsideration of the application in view of the amendments and remarks contained herein is respectfully requested.

The Examiner has repeated the requirement to elect a species and has stated that the claims will be "examined to the extent they read on R5 is L3 and M3 is